Mode
Text Size
Log in / Sign up
Early Phase 1 N=8 Basic Science

Benzo[a]Pyrene Ultralow Dose-Response Study

Environmental Exposure

Enrolled (actual)
8
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
[14C]-benzo[a]pyrene (Drug)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Oregon State University
Primary completion
Jan 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Peak Plasma Concentration Cmax
2.51; 5.68; 13.8; 8.99
SECONDARY
Time at Highest Plasma Concentration Tmax
0.5; 0.5; 0.5; 0.5
SECONDARY
Area Under Plasma Concentration Versus Time Curve AUC
12.2; 19.6; 88.5; 68.6
SECONDARY
Rate of Elimination (k1e)
12.2; 19.6; 88.5; 68.6

Summary

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following 4 oral doses of 25, 50, 10 and 250 ng (2.7-27 nCi).

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for women:
  • Age 21-65 (inclusive)
  • Must be post-menopausal or have had surgical sterilization to eliminate any possibility for fetal exposure
  • Willing to defer blood donation for one month before, throughout, and one month after completion of study activities
  • Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each study cycle (gas grilled foods acceptable)

Inclusion criteria for men:

  • Age 21-65 (inclusive)
  • Willing to defer blood donation for one month before, throughout, and one month after completion of study activities
  • Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each study cycle (gas grilled foods acceptable)

Exclusion Criteria

Exclusion criteria for both men and women:

  • Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or living with smoker
  • Regular use of medications that affect gut motility or nutrient absorption (e.g. cholestyramine, sucralfate, orlistat, pro- or anti-motility agents)
  • History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis)
  • Current or history of kidney or liver disease
  • Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not exclusionary)
  • Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03318978). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search